Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on May 30, 2024. The Company is an emerging growth company incorporated in Nevada with its principal executive offices in Boca Raton, Florida. Its common stock trades on The NASDAQ Stock Market LLC under the symbol INMB.
Key Financial Metrics
This filing is a Current Report regarding a corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The primary material event disclosed is the Company's inclusion in the Russell 3000 Index. This inclusion is scheduled to take effect at the open of US equity markets on July 1, 2024, following the conclusion of the 2024 Russell US Indexes annual reconstitution.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) regarding the index inclusion but provides no specific financial guidance, management commentary on future performance, or discussion of risks and contingencies within the text of this report.
Investor Verification Checklist
- Verify the effective date of the Russell 3000 Index inclusion (July 1, 2024).
- Review the attached press release (Exhibit 99.1) for additional details on the index reconstitution.
- Consult the Company's most recent 10-Q or 10-K filings for current financial metrics, as this 8-K contains none.
- Monitor trading volume and liquidity changes following the index inclusion date.